Reversal of endocrine resistance via N6AMT1-NEDD4L pathway-mediated p110α degradation

Abstract excerpt

<title>Abstract</title> <p>Approximately 70% of breast cancer (BC) cases are luminal-type (estrogen receptor-positive, ER+), suitable for endocrine therapy with tamoxifen as the most commonly used drug. However, about 30% of these patients develop tamoxifen resistance due to various mechanisms, primarily involving PI3K pathway activation through mutations or unknown pathways. Here, we discover, via bioinformatics...

Topics

Open a Topic to create a Post that cites this publication.

• Cell Survival
• CREB-Binding Protein
• Disease-Free Survival
• E1A-Associated p300 Protein
• Gene Dosage
• Histone Acetyltransferases
• TATA-Binding Protein Associated Factors
• Transcription Factor TFIID

Identifiers and source

Literature Corpus work

381a1c61-92b1-5c7b-8d4e-18c9349aed1b

DOI

10.21203/rs.3.rs-4738749/v1